Why AbbVie Inc. (ABBV) Is One of the Best Drug Stocks to Buy Now
We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...
Hosted on MSN22d
AbbVie’s newer immunology drugs are offsetting Humira’s decline, sending stock up 5%
AbbVie Inc.’s stock rose 7.7% Friday to lead S&P 500 gainers after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025, as its newer immunology drugs ...
Is AbbVie Stock a Buy Now?
In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...
AbbVie Appears Ready To Move Higher
AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...
BioSpace12d
AbbVie Gets FDA Approval for New Antibiotic in the Face of Rising Resistance
The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...
FiercePharma8d
UCB's Bimzelx outpacing AbbVie's Rinvoq, Skyrizi on awareness early in psoriatic arthritis launch: survey
UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ...
PMLiVE11d
AbbVie announces FDA approval of antibiotic combination for intra-abdominal infections
AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...
Nasdaq7d
Is AbbVie Stock a Buy Now?
The good news is that AbbVie has already found a replacement for Humira with two blockbuster drugs: Skyrizi and Rinvoq. While these drugs were developed for many of the same conditions as Humira ...